Preoperative oxaliplatin, docetaxel and capecitabine plus radiation found effective, relatively safe-- A. Agrawal, PhD
Wednesday, March 31, 2010 (Last Updated: 04/01/2010)
WEDNESDAY, March 31 (HealthDay News) -- Chemotherapy with oxaliplatin, docetaxel and capecitabine plus radiation therapy before surgery is effective and relatively safe in patients with localized operable esophageal cancer, according to a study published online March 29 in the Journal of Clinical Oncology.
As part of a phase I/II trial, David R. Spigel, M.D., and colleagues from the Sarah Cannon Research Institute and Tennessee Oncology in Nashville treated 59 patients (49 in phase II) with resectable esophageal cancer with preoperative oxaliplatin, docetaxel and capecitabine combined with radiation therapy.
Noting that the phase I study did not reveal any dose-limiting toxicity, the researchers found that 49 percent of patients in phase II had a pathologic complete response, 61 percent had an objective response, 6 percent had stable disease, and 2 percent had progressive disease. Of the 34 patients who underwent surgery, after a median follow-up of 116 weeks, median disease-free survival was 16.3 months and overall survival was 24.1 months. The most common serious toxicities were anorexia, dehydration, esophagitis, nausea and vomiting.
"Preoperative oxaliplatin, docetaxel and capecitabine plus radiation therapy is active and relatively safe in patients with locoregional esophageal cancer," Spigel and colleagues conclude. "Importantly, this therapy can be administered within eight weeks. This regimen warrants additional study in this setting and in combination with newer biologic agents."
The study was supported in part by Sanofi-Aventis. Several authors reported advisory, consulting and financial relationships with Sanofi-Aventis.
Copyright © 2010 HealthDay. All rights reserved.
September 01, 2014
November 25, 2015